Skip to main content
main-content

The independent medical news service

Kidney cancer

17-06-2022 | Oncology | News | Article

CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

06-06-2022 | Oncology | News | Article

Acetaminophen may blunt ICI response in people with cancer

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

04-06-2022 | Oncology | News | Article

Adjuvant everolimus may benefit RCC patients at high risk for recurrence

Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

27-04-2022 | Oncology | News | Article

Neurologic AE risk lower with ICIs vs chemotherapy

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

26-04-2022 | Oncology | News | Article

Cabozantinib shows promise for untreated collecting duct RCC

The BONSAI trial has demonstrated encouraging efficacy and manageable toxicity of cabozantinib in treatment-naïve patients with metastatic collecting duct renal cell carcinoma.

22-02-2022 | Oncology | News | Article

​​​​​​​NeoAvAx shows promise of neoadjuvant avelumab–axitinib for localized high-risk RCC

The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.

22-02-2022 | Oncology | News | Article

Sustained DFS benefit with adjuvant pembrolizumab in high-risk RCC

Extended follow-up data from the KEYNOTE-564 study show that adjuvant pembrolizumab continues to offer a disease-free survival benefit over placebo in people with renal cell carcinoma at an intermediate-high or high postsurgery recurrence risk.

20-02-2022 | Oncology | News | Article

​​​​​​​Combined nivolumab, axitinib treatment elicits good response in metastatic RCC

Combination treatment with nivolumab plus axitinib has achieved a high response rate in patients with metastatic renal cell carcinoma enrolled in a phase 1/2 trial.

19-01-2022 | Oncology | News | Article

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

23-12-2021 | Oncology | News | Article

EMA issues positive GU cancer opinions

Read more about the urothelial cancer and renal cell carcinoma decisions here

16-12-2021 | Oncology | News | Article

HLA-A*03 shows potential as a biomarker for ICI response

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

02-11-2021 | Oncology | News | Article

Radiotherapy without systemic therapy feasible for oligometastatic RCC

Definitive radiotherapy without systemic therapy may be a feasible strategy for the treatment of oligometastatic renal cell carcinoma, phase 2 study findings indicate.

21-10-2021 | Oncology | News | Article

Cabozantinib shows activity against RCC brain metastases

Cabozantinib has “considerable” intracranial activity in patients with advanced renal cell carcinoma and brain metastases, say the authors of a chart review published in JAMA Oncology.

19-10-2021 | Oncology | News | Article

EMA gives green light for first-line use of lenvatinib plus pembrolizumab in advanced RCC

Click through for the details of this positive opinion

18-10-2021 | Oncology | News | Article

PARP1 may predict ICI response in patients with advanced RCC

PARP1 could help identify patients with advanced clear cell renal cell carcinoma who are likely to benefit from immune checkpoint inhibitor treatment, with particular utility in those with PBRM1-mutated disease, indicate findings.

21-09-2021 | Oncology | News | Article

Drug-free interval feasible in metastatic RCC

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

17-08-2021 | Oncology | News | Article

FDA approves HIF-2α inhibitor belzutifan for VHL-associated tumors

Read more on this US FDA announcement here

16-08-2021 | Oncology | News | Article

Lenvatinib–pembrolizumab gets FDA nod for first-line advanced RCC

Click through for the details of this decision

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.